{"doi":"10.3724/abbs.2025257","title":"Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer","abstract":null,"journal":"Acta Biochimica et Biophysica Sinica","year":2026,"id":606294,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":7757,"name":"Jianming Lu","orcid":null,"position":1,"is_corresponding":false},{"id":1556452,"name":"Shanshan Mo","orcid":null,"position":2,"is_corresponding":false},{"id":1556453,"name":"Jipu Liu","orcid":null,"position":3,"is_corresponding":false},{"id":1556454,"name":"Chuanfan Zhong","orcid":null,"position":4,"is_corresponding":false},{"id":1556455,"name":"Yongding Wu","orcid":null,"position":5,"is_corresponding":false},{"id":1556456,"name":"Fen Zou","orcid":null,"position":6,"is_corresponding":false},{"id":1556457,"name":"Jianheng Ye","orcid":null,"position":7,"is_corresponding":false},{"id":1556458,"name":"Zhaodong Han","orcid":null,"position":8,"is_corresponding":false},{"id":983323,"name":"Yuxiang Liang","orcid":"0000-0002-3321-5572","position":9,"is_corresponding":false},{"id":610813,"name":"Le Zhang","orcid":"0000-0003-1841-1986","position":10,"is_corresponding":false},{"id":1556459,"name":"Fengping Liu","orcid":null,"position":11,"is_corresponding":false},{"id":1556460,"name":"Weide Zhong","orcid":null,"position":12,"is_corresponding":false},{"id":1556451,"name":"Zhouda Cai","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer","abstract":"<p indent=\"0mm\">Lethal prostate cancer is marked by tumor heterogeneity and resistance to androgen receptor signaling inhibitors (ARSIs). In this study we identify glycolysis as a driver of disease progression and therapy resistance. Using single-sample gene set enrichment analysis (ssGSEA) on the SU2C cohort, we demonstrate that elevated glycolysis activity is associated with poor progression-free and overall survival. The glycolysis-based prognostic score (GLY score) is derived from the HALLMARK_GLYCOLYSIS gene set which includes <italic>CLN6</italic>, <italic>SDHC</italic>, <italic>B4GALT2</italic>, <italic>RPE</italic>, <italic>NANP</italic>, and <italic>KIF20A</italic>, via LASSO-Cox regression. The GLY score effectively stratifies risk in the SU2C and WDCT cohorts, with higher scores predicting worse outcomes and increased SYNE1 mutation frequency. Pan-cancer analysis across TCGA datasets confirm its prognostic value. <italic>In vitro</italic>, enzalutamide-resistant prostate cancer cell lines exhibit heightened glycolysis, and 2-DG inhibition reverses this effect, restoring drug sensitivity. <italic>CLN6</italic> knockdown reduces glycolytic activity and cell proliferation. The GLY score offers robust prognostic value, and CLN6 represents a promising therapeutic target for precision medicine in lethal prostate cancer.","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41527450","pmcid":null,"openalex_id":"https://openalex.org/W7118118793","authors":[],"funders":[],"total_grants":0,"fwci":15.3716,"citation_percentile":0.97821815,"influential_citations":0,"citation_trend":[{"year":2026,"count":2}],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://doi.org/10.3724/abbs.2025257","host_type":"journal"},{"url":"https://doi.org/10.3724/abbs.2025257","host_type":"publisher"},{"url":"https://www.sciengine.com/sci-open/api/v1/open/file/pdf/0493D5A317BC41E7B67DABF684689ACA","host_type":"publisher"},{"url":"https://www.sciengine.com/doi/10.3724/abbs.2025257","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41527450","host_type":"repository"}],"fields_of_study":["Prostate Cancer Treatment and Research","Clusterin in disease pathology","Cancer, Hypoxia, and Metabolism"],"mesh_terms":[],"keywords":["Prostate cancer","Androgen receptor","Glycolysis","Gene knockdown","Reprogramming","Prostate","Disease","Androgen deprivation therapy","Enzalutamide","Cln6","Lethal Prostate Cancer","Ar Signaling Inhibitor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"No poverty"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T04:15:29.233655Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}